Placebo to match LY2951742

DRUG2 trials

Sponsors

Eli Lilly & Co.

Conditions

Chronic MigraineMigraine

Phase 3

I5Q-MC-CGAT:A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study

Active, not recruitingCTIS2023-505835-11-00

Eli Lilly & Co.Chronic Migraine

Start: 2021-03-12Target: 93Updated: 2025-11-05

I5Q-MC-CGAS: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study

Active, not recruitingCTIS2023-505836-36-00

Eli Lilly & Co.Migraine

Start: 2021-03-12Target: 64Updated: 2025-11-05